Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KIT mutant |
| Therapy | Nilotinib |
| Indication/Tumor Type | mucosal melanoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KIT mutant | mucosal melanoma | predicted - sensitive | Nilotinib | Phase II | Actionable | In a Phase II trial (NICAM), Tasigna (nilotinib) treatment demonstrated activity in patients with acral (n=6) or mucosal melanoma (n=20) harboring KIT mutations, resulting in a progression-free survival at 6 months in 25% (6/24) of the patients, a median-progression free survival of 3.7 months, objective response rate at 12 weeks of 19% (5/26), and median overall survival of 7.7 months (PMID: 38417447). | 38417447 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38417447) | Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial. | Full reference... |